支气管哮喘(简称哮喘)是影响全球各个年龄阶段人群健康的疾病~([1])。自2002年全球哮喘防治倡议(GINA)发表以来,规范了哮喘的治疗:控制药物+缓解药物,临时发作时使用短效的β2受体激动剂~([2]),再依据Nathan等~([3])的哮喘控制测试(ACT评分)进行治疗强度的调整。但哮喘控制率仍较低:亚太地区仅2.9%,我国为2%,全球1年最高约为80%~([4-6])。本研究组认为哮喘控制率低的原因有: Bronchial asthma (asthma) is a disease that affects the health of people of all ages around the world ~ ([1]). Since the Global Initiative for Asthma Prevention and Control (GINA) was published in 2002, asthma has been prescribed for the treatment of asthma: drug-controlled and drug-relief, short-acting β2 agonist ~ ([2]) for temporary attacks, and Nathan et al. [3]) asthma control test (ACT score) to adjust the intensity of treatment. However, the rate of asthma control is still low: only 2.9% in Asia Pacific, 2% in China and about 80% in the world in one year ([4-6]). The team believes that the reasons for the low rate of asthma control are: